natgillin/translations-raw huggingface dataset:
Table 1 presents vaccine-related adverse reactions which were observed among recipients of Silgard at a frequency of at least 1.0% and also at a greater frequency than observed among placebo recipients.
Tablica 1 prikazuje nuspojave povezane s cjepivom, koje su opažene u osoba koje su primile Silgard, s učestalošću od najmanje 1,0%, i s većom učestalosti nego u ispitanika koji su primili placebo.
- If you have any further questions, please ask your doctor or pharmacist.
- Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
Table 4: Results for CIN 2/3 or AIS in Type-Specific HPV-Naïve Individuals
Tablica 4: Rezultati za CIN 2/3 odnosno AIS u pojedinaca koji nisu bili izloženi specifičnom tipu HPV(konačni rezultati ispitivanja)
Women who were already infected with one or more vaccine-related HPV types prior to vaccination were protected from clinical disease caused by the remaining vaccine HPV
Žene koje su prije cijepljenja već bile inficirane jednim ili više tipova HPV-a sadržanim u cjepivu bile su zaštićene od kliničke bolesti prouzročene preostalim tipovima HPV-a sadržanim u cjepivu.
HPV 11 885 HPV 16 882 HPV 18 887
HPV 6 915 HPV 11 915 HPV 16 913 HPV 18 920
The second dose should be administered at least one month after the first dose and the third dose should be administered at least 3 months after the second dose.
Drugu dozu treba primijeniti najmanje mjesec dana nakon prve doze, a treću dozu treba primijeniti najmanje 3 mjeseca nakon druge doze.
This assay measures antibodies against a single neutralizing epitope for each individual HPV type.
Ovaj test mjeri protutijela na jedan neutralizacijski epitop za svaki pojedini tip HPV-a.
The active substances are: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16, and 18).
Djelatne tvari su: visoko pročišćeni neinfektivni protein svakog pojedinog tipa humanog papilomavirusa (6, 11, 16 i 18).
In only 1 of 11 specimens HPV 16 was found (at Month 32.5) and was not detected in tissue excised during LEEP (Loop Electro-Excision Procedure).
Od 11 uzoraka samo u jednome je pronađen HPV tip 16 (u 32,5 mjesecu praćenja) te nije pronađen u tkivu dobivenom elektrokirurškom ekscizijom s pomoću petlje (LEEP).
The term "premalignant genital lesions" in section 4.1 corresponds to high-grade cervical intraepithelial neoplasia (CIN 2/3), high-grade vulvar intraepithelial neoplasia (VIN 2/3) and highgrade vaginal intraepithelial neoplasia (VaIN 2/3).
Izraz "premaligne genitalne lezije" iz dijela 4.1 odnosi se na cervikalnu intraepitelnu neoplaziju visokoga stupnja (CIN 2/3), vulvarnu intraepitelnu neoplaziju visokoga stupnja (VIN 2/3) odnosno vaginalnu intraepitelnu neoplaziju visokoga stupnja (VaIN 2/3).
In a clinical trial of 843 healthy adolescent males and females 11-17 years of age, administration of the first dose of Silgard concomitantly with a combined diphtheria, tetanus, pertussis [acellular, component] and poliomyelitis [inactivated] booster vaccine showed that there was more injection-site swelling and headache reported following concomitant administration.
U kliničkom ispitivanju u kojem je sudjelovalo 843 zdravih adolescenata oba spola u dobi od 11 do 17 godina u kojih se prva doza cjepiva Silgard primijenila istodobno s docjepljivanjem kombiniranim cjepivom protiv difterije, tetanusa, pertusisa [acelularno, komponentno] i poliomijelitisa [inaktivirano] pokazalo se da je nakon istodobne primjene bilo prijavljeno više oticanja na mjestu primjene cjepiva i glavobolja.
The preferred site is the deltoid area of the upper arm or in the higher anterolateral area of the thigh.
Najpogodnije mjesto za primjenu injekcije je deltoidno područje nadlaktice ili gornji dio anterolateralnog područja bedra.
• Inject immediately using the intramuscular (IM) route, preferably in the deltoid area of the upper arm or in the higher anterolateral area of the thigh.
• Odmah ubrizgajte intramuskularnim (i.m.) putem, po mogućnosti u deltoidno područje nadlaktice ili gornje anterolateralno područje bedra.
These data are intended to guide healthcare professionals in case of temporary temperature excursion only.
Ovi su podaci namijenjeni kao smjernica zdravstvenim radnicima samo u slučaju privremenog povišenja ili sniženja temperature čuvanja.
The impact of Silgard against the overall risk for external genital lesions was evaluated after the first dose in 2,545 individuals enrolled in the Phase III efficacy trial (Protocol 020).
Utjecaj cjepiva Silgard protiv cjelokupnog rizika od vanjskih genitalnih lezija procjenjivan je nakon primjene prve doze u 2545 osoba uključenih u Fazu III ispitivanja djelotvornosti (Protokol 020).
Individuals 14 years of age and older Silgard should be administered according to a 3-dose (0.5 ml at 0, 2, 6 months) schedule.
Pojedinci u dobi od 14 godina i stariji Silgard treba primijeniti prema rasporedu za 3 doze (0,5 ml primijenjeno sa 0, 2 i 6 mjeseci).
Anal Intraepithelial Neoplasia (AIN) Grade 2/3 (moderate to high-grade dysplasia) was used in the clinical trials as a surrogate marker for anal cancer.
Analna intraepitelijalna neoplazija (AIN) stupnja 2/3 (srednje teška do teška displazija) korištena je u kliničkim ispitivanjima kao zamjenski marker za karcinom anusa.
The clinical relevance of these findings is unknown.
Nije poznata klinička važnost ovih nalaza.
• Shake well before use to make a suspension.
• Prije primjene dobro protresite kako bi se dobila suspenzija.
Efficacy results are presented for the combined analysis of study protocols.
Prikazani rezultati djelotvornosti objedinjuju analize više protokola ispitivanja.
See sections 4.4 and 5.1 for important information on the data that support this indication.
Za važne informacije i podatke koji podupiru ovu indikaciju, vidjeti dijelove 4.4 i 5.1.
The term "premalignant anal lesions" in section 4.1 corresponds to high-grade anal intraepithelial neoplasia (AIN 2/3).
Izraz "premaligne analne lezije" u dijelu 4.1 odgovara analnoj intraepitelnoj neoplaziji visokog stupnja (AIN 2/3).
Silgard was efficacious against HPV disease caused by each of the four vaccine HPV types.
Silgard se pokazao djelotvornim protiv bolesti uzrokovanih bilo kojim od četiri tipova HPV-a sadržanih u cjepivu.
The vaccine should not be mixed in the same syringe with any other vaccines and solutions.
Cjepivo se ne smije miješati s drugim cjepivima i otopinama u istoj štrcaljki.
It is recommended that individuals who receive a first dose of Silgard complete the vaccination course
Preporučuje se da osobe koje prime prvu dozu cjepiva Silgard završe seriju cijepljenja također s
In males, dizziness was not observed at a greater frequency in vaccine recipients than in placebo recipients.
U muškaraca, omaglica nije češće opažena u osoba koje su primile cjepivo u odnosu na osobe koje su primile placebo.
The vaccine is not used to treat HPV related diseases.
To se cjepivo ne koristi u liječenju bolesti koje izaziva infekcija HPV-om.
Silgard is given as an injection by your doctor.
Silgard Vam daje liječnik injekcijom.
The full recommended dose of the vaccine should be used.
Mora se primijeniti cijela preporučena doza cjepiva.
In all clinical trials, individuals who had received immunoglobulin or blood-derived products during the 6 months prior to the first vaccine dose were excluded.
Pojedinci koji su primili imunoglobulin ili pripravke dobivene iz krvi unutar 6 mjeseci prije prvoga cijepljenja bili su isključeni iz svih kliničkih ispitivanja.
Merck Sharp & Dohme Corp. Sumneytown Pike P.O.Box 4
Sumneytown Pike P.O.Box 4
In general, the adverse event profile reported with overdose was comparable to recommended single
Općenito, zabilježeni štetni događaji vezani uz predoziranje bili su slični onima vezanim uz preporučene doze cjepiva Silgard.
It is also not intended to prevent progression of other established HPV-related lesions.
Također nije namijenjeno sprječavanju progresije drugih već postojećih lezija
In addition, a subset of vaccinated women who received a challenge dose of Silgard 5 years after the onset of vaccination, exhibited a rapid and strong anamnestic response that exceeded the anti-HPV GMTs observed 1 month Postdose 3.
Usto je u jednoj podskupini cijepljenih žena koje su primile provokacijsku dozu (eng. challenge dose) cjepiva Silgard 5 godina nakon početka cijepljenja zamijećen brz i snažan anamnestički odgovor koji je bio viši od geometrijskog srednjeg titra protutijela na HPV zabilježenog mjesec dana nakon 3. doze cjepiva.
Silgard will be given as an injection through the skin into the muscle (preferably the muscle of the
Silgard se daje u obliku injekcije kroz kožu u mišić (po mogućnosti u mišić nadlaktice ili bedra).
Three clinical studies (Protocols 016, 018 and 020) were used to compare the immunogenicity of Silgard in 9- to 15-year-old boys to 16- to 26-year-old men.
Tri su se klinička ispitivanja (Protokoli 016, 018 i 020) koristila za usporedbu imunogenosti cjepiva Silgard u dječaka u dobi od 9 do 15 godina i mladih muškaraca u dobi od 16 do 26 godina.
In all populations (women 9 - 45 years, men 9 - 26 years), peak anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 GMTs cLIA were observed at Month 7.
U svim populacijama (žene u dobi od 9 do 45 godina, muškarci u dobi od 9 do 26 godina), vršni anti-HPV 6, anti-HPV 11, anti-HPV 16 i anti-HPV 18 GMT-ovi na cLIA testu bili su opaženi u 7. mjesecu ispitivanja.
However, in individuals who are already infected with one or more of the vaccine HPV types, Silgard can still protect against diseases associated with
Međutim, pojedince koji su već zaraženi jednim ili više tipova HPV-a sadržanim u cjepivu, Silgard i dalje može zaštititi od bolesti prouzročenih preostalim tipovima HPV-a sadržanih u cjepivu.
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCES AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
PROIZVOĐAČI BIOLOŠKIH DJELATNIH TVARI I PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE
Evidence of an anamnestic response was seen in vaccinated women who were seropositive to relevant HPV type(s) prior to vaccination.
Anamnestički je odgovor zamijećen u cijepljenih žena sa seropozitivnim nalazima na odgovarajuće tipove HPV-a prije cijepljenja.
Overall 12% of the combined study population had an abnormal Pap test suggestive of CIN at Day 1.
Ukupno je 12% populacije iz svih ispitivanja imalo 1-og dana ispitivanja patološke nalaze Papa testa koji su ukazivali na CIN.
The impact of Silgard on rates of biopsy and treatment of EGL regardless of causal HPV types was evaluated in 2,545 individuals enrolled in Protocol 020.
Utjecaj cjepiva Silgard na stope biopsije i liječenje vanjskih genitalnih lezija bez obzira na HPV tipove koji ih uzrokuju procjenjivana je u 2545 osoba koje su bile uključene u Protokol 020.
Very commonly (more than 1 in 10 patients), side effects found at the injection site include: pain, swelling and redness.
Vrlo često (više od 1 na 10 osoba), nuspojave zamijećene na mjestu injekcije obuhvaćaju: bol, oticanje i crvenilo.
The median duration of follow-up for these studies was 4.0, 3.0, 3.0, and 3.0 years for Protocol 005, Protocol 007, Protocol 013, and Protocol 015, respectively.
Medijan trajanja praćenja iznosio je 4,0 godina u protokolu 005, 3,0 godina u protokolu 007, 3,0 godina u protokolu 013 te 3,0 godina u protokolu 015.
HPV types 16 and 18 are responsible for approximately 70% of cervical cancer cases, 75-80% of anal cancer cases; 70% of HPV-related pre-cancerous lesions of the vulva and vagina; 75% of HPV related pre-cancerous lesions of the anus.
Tipovi HPV-a 16 i 18 odgovorni su za oko 70% oboljenja od raka vrata maternice, 75-80% slučajeva raka anusa; 70% prekanceroznih lezija stidnice i rodnice povezanih s HPV-om; te 75% prekanceroznih lezija anusa povezanih s HPV-om.
In the Full Analysis Set (FAS) population, the benefit of the vaccine with respect to the overall incidence of EGL was lower, with a reduction of 59.3% (95% CI: 40.0, 72.9), as Silgard does not impact the course of infections or disease that are present at vaccination onset.
U analizi cjelokupne uključene populacije korist od cjepiva u odnosu na cjelokupnu incidenciju pojave vanjskih genitalnih lezija bila je niža, uz smanjenje od 59,3% (95% CI: 40,0; 72,9) pošto Silgard ne utječe na tijek infekcije ili bolesti prisutne na početku cijepljenja.
0.5 ml suspension in a pre-filled syringe (glass) with plunger stopper (siliconized FluroTec-coated bromobutyl elastomer or non-coated chlorobutyl elastomer) and a tip cap (bromobutyl) without needle or with one or two needle(s) - pack size of 1, 10 or 20.
0,5 ml suspenzije u napunjenoj štrcaljki (staklo) s čepom klipa (silikonizirani bromobutil elastomer obložen FluroTecom ili neobloženi klorobutil elastomer) i zatvaračem vrha (bromobutil), bez igle ili s jednom ili dvije igle, u pakiranjima od 1, 10 ili 20.
Silgard is available in packs of 1, 10 or 20 vials.
Silgard je dostupan u pakiranju od 1, 10 ili 20 bočica.
The individuals who were monitored using VRC-aided surveillance included 10,088 individuals (6,995 females 9 to 45 years of age and 3,093 males 9 to 26 years of age at enrolment) who received Silgard and 7,995 individuals (5,692 females and 2,303 males) who received placebo.
Ukupno je 10 088 ispitanika koji su nadzirani pomoću kartice za izvještavanje o cijepljenju primilo je Silgard (6995 žena u dobi od 9 do 45 godina i 3093 muškaraca u dobi od 9 do 26 godina u trenutku uključenja), dok je 7995 ispitanika (5692 žena i 2303 muškaraca) primilo placebo.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
U slučaju bilo kakvih pitanja u vezi s primjenom ovog lijeka obratite se liječniku ili ljekarniku.
The immunogenicity of Silgard was assessed in 20,132 (Silgard n = 10,723; placebo n = 9,409) girls and women 9 to 26 years of age, 5,417 (Silgard n = 3,109; placebo n = 2,308) boys and men 9 to 26 years of age and 3,819 women 24 to 45 years of age (Silgard n = 1,911, placebo n = 1,908).
Imunogenost cjepiva Silgard ispitala se u 20 132 (Silgard n = 10 723; placebo n = 9409) djevojaka i žena u dobi od 9 do 26 godina, 5417 (Silgard n = 3109; placebo n = 2308) dječaka i muškaraca u dobi od 9 do 26 godina i 3819 žena u dobi od 24 do 45 godina (Silgard n = 1911, placebo n = 1908).
Silgard can be given with a Hepatitis B vaccine or with a combined booster vaccine containing diphtheria (d) and tetanus (T) with either pertussis [acellular, component] (ap) and/or poliomyelitis [inactivated] (IPV) (dTap, dT-IPV, dTap-IPV vaccines) at a separate injection site (another part of your body, e.g. the other arm or leg) during the same visit.
Silgard se može primijeniti istovremeno s cjepivom protiv hepatitisa B ili kod docjepljivanja kombiniranim cjepivom protiv difterije (d) i tetanusa (T) zajedno s cjepivom protiv hripavca [acelularno, komponento] (ap) i/ili poliomijelitisa [inaktivirano] (IPV) (dTap, dT-IPV, dTap-IPV cjepiva), ali u različito mjesto injiciranja (drugi dio tijela, npr. u drugu ruku ili nogu), i to tijekom istog
In addition, in clinical trials adverse reactions that were judged to be vaccine- or placebo-related by the study investigator were observed at frequencies lower than 1%:
Dodatno, u kliničkim ispitivanjima zapažene su nuspojave s učestalošću manjom od 1%, za koje su ispitivači ocijenili da su povezane s cjepivom odnosno placebom:
Vaccination with Silgard is intended to protect against diseases caused by Human Papillomavirus (HPV) types 6, 11, 16, and 18.
Svrha cijepljenja cjepivom Silgard je zaštita od bolesti uzrokovanih ljudskim papilomavirusom (HPV) tipova 6, 11, 16 i 18.
Silgard is a vaccine for use from the age of 9 years for the prevention of: - premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV)
Silgard je cjepivo namijenjeno osobama od 9. godine starosti za prevenciju: - premalignih genitalnih lezija (vrata maternice, vulve i vagine), premalignih analnih lezija te raka vrata maternice i raka anusa prouzročenih određenim onkogenim tipovima humanog
In the ITT population the corresponding reduction was 23.9% (95% CI: 15.2, 31.7).
U populaciji predviđenoj za liječenje ovo je smanjenje iznosilo 23,9% (95% CI: 15,2; 31,7).
Efficacy was 68.2% (95% CI: 17.9, 89.5; 6 vs. 20 cases [n = 832 from studies in young and adult women combined]) against HPV 16- and 18-related persistent infection in women 16 to 45 years.
Djelotvornost je bila 68,2% (95% CI: 17,9; 89,5; 6 naspram 20 slučajeva [n= 832 iz ispitivanja u mladih i odraslih žena zajedno]) kad se radilo o perzistentnoj infekciji prouzročenoj HPV-om 16 i 18 u žena u dobi od 16 do 45 godina.
Depending on HPV type, 60-96% and 78-98% of subjects were seropositive by cLIA and IgG LIA respectively 10 years after vaccination (see Table 8).
Ovisno o tipu HPV-a, 60-96% ispitanika bilo je seropozitivno na cLIA testu, a 78-98% na IgG LIA testu 10 godina nakon cijepljenja (vidjeti
Silgard is available in packs of 1, 10 or 20 pre-filled syringes.
Silgard je dostupan u pakiranju od 1, 10 ili 20 napunjenih štrcaljki.
In the FAS population, the corresponding reduction was 45.7% (95% CI: 29.0, 58.7) and 38.1% (95% CI: 19.4,
U populaciji cjelokupnog seta analize, odgovarajuće smanjenje bilo je 45,7% (95% CI: 29,0; 58,7) i 38,1% (95% CI: 19,4; 52,6).
Efficacy was based on reductions in HPV 31-related CIN 2/3 or AIS Efficacy was based on reductions in HPV 31-, 33-, 52-, and 58-related CIN 2/3 or AIS Includes assay-identified non-vaccine HPV types 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59.
Djelotvornost se temeljila na smanjenju broja CIN-a 2/3 odnosno AIS-a povezanih s tipom HPV-a 31 Djelotvornost se temeljila na smanjenju broja CIN-a 2/3 odnosno AIS-a povezanih s tipovima HPV-a 31, 33, 52 i 58 Uključuje tipove HPV-a 31, 33, 35, 39, 45, 51, 52, 56, 58 i 59 utvrđene pretragom, a koji nisu obuhvaćeni cjepivom.
Overall, 83% of men (87% of heterosexual subjects and 61% of MSM subjects) were naïve (PCR negative and seronegative) to all 4 HPV types at enrolment.
U vrijeme uključivanja sveukupno 83% muškaraca (87% heteroseksualnih muškaraca i 61% muškaraca koji su imali spolne odnose sa drugim muškarcima) nije imalo infekciju (PCR negativni i seronegativni) s niti jednim od 4 HPV tipa.
The use of Silgard should be in accordance with official recommendations.
Silgard treba primjenjivati sukladno službenim preporukama.
This population approximates to the general population of women with respect to prevalence of HPV infection or disease at enrolment.
Ova je populacija slična općoj populaciji žena s obzirom na prevalenciju infekcije ili bolesti izazvane HPV-om u trenutku uključenja.
Any unused vaccine or waste material should be disposed of in accordance with local requirements.
Neiskorišteni lijek ili otpadni materijal valja zbrinuti sukladno lokalnim propisima.
Silgard produces type-specific antibodies and has been shown in clinical trials to prevent HPV 6-, 11-, 16-, and 18-related diseases in women 16-45 years of age and in men 16-26 years of age.
Silgard potiče nastanak protutijela specifičnih na tip virusa i, kako je pokazano u kliničkim ispitivanjima, sprječava bolesti uzrokovane HPV tipovima 6, 11, 16 i 18 u žena u dobi od 16 do 45 godina i u muškaraca u dobi od 16 do 26 godina.
As with any vaccine, vaccination with Silgard may not result in protection in all vaccine recipients.
Kao i sa bilo kojim cjepivom, cijepljenje cjepivom Silgard ne mora pružiti zaštitu svima koji su primili cjepivo.
Do not use this vaccine after the expiry date which is stated on the syringe label and the outer carton (after EXP).
Ovo cjepivo se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na naljepnici štrcaljke i na vanjskom pakiranju iza oznake "EXP".
Commonly (more than 1 in 100 patients), side effects found at the injection site include: bruising, itching, pain in extremity.
Često (više od 1 na 100 osoba), nuspojave zamijećene na mjestu injekcije obuhvaćaju: modrice, svrbež, bolove u udovima.
AntiHBs geometric mean antibody titres were lower on co-administration, but the clinical significance of
Srednji geometrijski titar protutijela na HBs bio je niži kod istodobne primjene, ali značaj ovog opažanja za kliničku primjenu nije poznat.
The impact of Silgard on rates of Definitive Cervical Therapy Procedures regardless of causal HPV types was evaluated in 18,150 individuals enrolled in Protocol 007, Protocols 013 and 015.
Utjecaj cjepiva Silgard na stope konačnih postupaka terapije vrata maternice bez obzira koji je tip HPV-a uzročnik, procijenjen je u 18 150 ispitanika obuhvaćenih Protokolima 007, 013 i 015.
Not known Injection-site cellulitis * Not known Idiopathic thrombocytopenic purpura*, lymphadenopathy* Not known Hypersensitivity reactions including anaphylactic/anaphylactoid reactions* Nervous system disorders Very common Headache Not known Acute disseminated encephalomyelitis*, Dizziness Guillain-Barré syndrome*, syncope sometimes accompanied by tonic-clonic movements*
Nuspojava nepoznato celulitis na mjestu injiciranja* Poremećaji krvi i limfnog sustava nepoznato idiopatska trombocitopenična purpura*, limfadenopatija* Poremećaji imunološkog sustava nepoznato reakcije preosjetljivosti uključujući anafilaktičke/anafilaktoidne reakcije*
When Silgard was given with a combined diphtheria, tetanus, pertussis [acellular, component] and poliomyelitis [inactivated] booster vaccine during the same visit, there was more headache and injection-site swelling.
Kad se Silgard davao istovremeno kod docjepljivanja kombiniranim cjepivom protiv difterije, tetanusa, hripavca [acelularna komponenta] i poliomijelitisa [inaktivirano] prilikom istog posjeta liječniku, bilo je više glavobolja i otoka na mjestu primjene injekcije.
Alternatively, Silgard can be administered according to a 3-dose (0.5 ml at 0, 2, 6 months) schedule.
Silgard se također može primijeniti i prema rasporedu za 3 doze (0,5 ml primijenjeno sa 0, 2 i 6 mjeseci).
Please speak to your doctor for more information.
Dodatne podatke možete zatražiti od svog liječnika.
The vaccine is therefore not indicated for treatment of cervical cancer, high-grade cervical, vulvar, and vaginal dysplastic lesions or genital warts.
Stoga ovo cjepivo nije indicirano za liječenje raka vrata maternice, lezija visokog stupnja vrata maternice, stidnice i rodnice ili liječenje genitalnih bradavica.
HPV 16 and HPV 18 are estimated to be responsible for approximately 70% of cervical cancers and 75-80% of anal cancers; 80% of adenocarcinoma in situ (AIS); 45-70% of high-grade cervical intraepithelial neoplasia (CIN 2/3); 25% of low grade cervical intraepithelial neoplasia (CIN 1); approximately 70% of HPV related high-grade vulvar (VIN 2/3) and vaginal (VaIN 2/3) intraepithelial neoplasia and 80% of HPV related high-grade anal (AIN 2/3) intraepithelial neoplasia.
Procjenjuje se da su HPV 16 i 18 odgovorni za oko 70% slučajeva raka vrata maternice i 75-80% slučajeva raka anusa; 80% adenokarcinoma in situ (AIS); 45-70% cervikalnih intraepitelnih neoplazija visokoga stupnja (CIN 2/3); 25% cervikalnih intraepitelnih neoplazija niskoga stupnja (CIN 1); oko 70% vulvarnih intraepitelnih neoplazija visokoga stupnja povezanih s HPV-om (VIN 2/3) odnosno vaginalnih intraepitelnih neoplazija visokoga stupnja (VaIN 2/3) te 80% analnih intraepitelnih neoplazija visokog stupnja (AIN 2/3 ) povezanih s HPV-om.
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of
Nuspojave možete prijaviti izravno putem nacionalnog sustava za prijavu nuspojava: navedenog u Dodatku V.
Type-specific immunoassays, competitive Luminex-based immunoassay (cLIA), with type-specific standards were used to assess immunogenicity to each vaccine type.
Za procjenu imunološkog odgovora na svaki pojedini tip obuhvaćen cjepivom rabljeni su imunotestovi specifični za pojedine tipove i kompetitivni cLIA test (engl. competitive Luminex-based immunoassay), oslanjajući se na standarde za svaki pojedini tip.
C. OTHER CONDITIONS AND REQUIREMENTS OF THE
OSTALI UVJETI I ZAHTJEVI ODOBRENJA